Endocrine Abstracts

Introduction: The tyrosine kinase inhibitor (TKI) lenvatinib, used in radioiodine-refractory differentiated thyroid cancer, is usually well-tolerated. However, severe side effects can occur. We describe a life-threatening complication under lenvatinib, followed by a challenging treatment with levothyroxine (LT4).Case Report: A 62-year-old man was diagnosed with a bone-metastasized Hurthle cell thyroid carcinoma (pT3N0M1). He underwent a total thyroidecto...